Երկիր: Կանադա
Լեզու: անգլերեն
Աղբյուրը: Health Canada
CAFFEINE CITRATE
OMEGA LABORATORIES LIMITED
N06BC01
CAFFEINE
20MG
SOLUTION
CAFFEINE CITRATE 20MG
INTRAVENOUS
15G/50G
Prescription
Active ingredient group (AIG) number: 0162054001; AHFS:
APPROVED
2022-04-25
Product Monograph (Caffeine Citrate Injection USP) Page 1 of 25 PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR CAFFEINE CITRATE INJECTION USP SOLUTION, 20 MG / ML, INTRAVENOUS / ORAL (EACH ML CONTAINS 20 MG CAFFEINE CITRATE, EQUIVALENT TO 10 MG CAFFEINE BASE) USP PSYCHOANALEPTICS, XANTHINE DERIVATIVES ATC CODE: N06BC01 OMEGA LABORATORIES LIMITED 11 177 HAMON STREET MONTREAL, QUEBEC H3M 3E4 DATE OF INITIAL APPROVAL: April 20, 2022 Submission Control No: 251391 Product Monograph (Caffeine Citrate Injection USP) Page 2 of 25 TABLE OF CONTENTS............................................................................................................ 2 PART I: HEALTH PROFESSIONAL INFORMATION .......................................................... 4 1 INDICATIONS ................................................................................................................ 4 1.1 Pediatrics ..................................................................................................................... 4 1.2 Geriatrics ..................................................................................................................... 4 2 CONTRAINDICATIONS................................................................................................ 4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX..................................................... 5 4 DOSAGE AND ADMINISTRATION ............................................................................. 5 4.1 Dosing Considerations ................................................................................................. 5 4.2 Recommended Dose and Dosage Adjustment................................................................ 5 4.3 Administration ............................................................................................................. 7 5 OVERDOSAGE............................................................................................................... 8 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING............. Կարդացեք ամբողջական փաստաթուղթը